A 28-year-old man with biopsy-proven membranous nephropathy and nephrotic syndrome (proteinuria 6.5 g/day) is being evaluated for the underlying etiology. Serological workup shows negative ANA, negative anti-dsDNA, and normal complement levels. Which investigation is most specific for identifying secondary membranous nephropathy and guiding further management?

Explanation

## Investigation for Etiology of Membranous Nephropathy ### Clinical Context This patient has biopsy-confirmed membranous nephropathy with nephrotic syndrome. The negative autoimmune markers (ANA, anti-dsDNA) and normal complement make lupus and other systemic diseases unlikely. The key question is: **primary (idiopathic) vs. secondary membranous nephropathy?** ### Anti-PLA2R Antibody: The Gold Standard for Primary Membranous Nephropathy **Key Point:** Anti-phospholipase A2 receptor (PLA2R) antibodies are present in 70–80% of patients with primary (idiopathic) membranous nephropathy and are virtually absent in secondary forms. **High-Yield:** PLA2R is a podocyte antigen that is the major target of autoimmunity in primary membranous nephropathy. Detection of anti-PLA2R antibodies: - Confirms primary membranous nephropathy - Excludes secondary causes (malignancy, infection, drugs, autoimmune disease) - Predicts disease course and response to immunosuppressive therapy - Helps guide treatment intensity ### Diagnostic Algorithm for Membranous Nephropathy ```mermaid flowchart TD A[Membranous Nephropathy on Biopsy]:::outcome --> B{Clinical & Serological Features}:::decision B -->|Negative ANA, anti-dsDNA, normal C3/C4| C[Check Anti-PLA2R]:::action C -->|Positive| D[Primary Membranous Nephropathy]:::outcome C -->|Negative| E[Consider Secondary Causes]:::action B -->|Positive ANA/anti-dsDNA or low complement| F[Lupus Nephritis]:::outcome E --> G{Age >60 or Hematuria?}:::decision G -->|Yes| H[Screen for Malignancy]:::action G -->|No| I[Check HBsAg, HCV Ab]:::action H --> J[Chest X-ray, CT abdomen/pelvis]:::action I --> K[Serology & Immunofixation]:::action ``` ### Comparison: Anti-PLA2R vs. Other Investigations | Investigation | Utility in Membranous Nephropathy | Sensitivity | Specificity | |---------------|-----------------------------------|-------------|-------------| | **Anti-PLA2R** | Confirms primary MN; predicts prognosis | 70–80% | >95% | | **Immunofixation** | Detects monoclonal protein (secondary MN) | 10–15% | High | | **HBsAg/HCV Ab** | Identifies viral-associated MN | Variable | High | | **Chest X-ray** | Screens for occult malignancy | Low | Moderate | | **ANA/anti-dsDNA** | Excludes lupus | N/A | High | **Clinical Pearl:** In a young patient (age 28) with negative autoimmune markers and normal complement, anti-PLA2R positivity strongly supports primary membranous nephropathy and makes extensive malignancy screening less urgent. Conversely, anti-PLA2R negativity would warrant investigation for secondary causes (occult malignancy, HBV/HCV, monoclonal protein). ### Management Implications - **Anti-PLA2R positive:** Immunosuppressive therapy (corticosteroids + cyclophosphamide or calcineurin inhibitors) is indicated - **Anti-PLA2R negative:** Search for and treat underlying cause (e.g., malignancy, HBV, drug-induced) - **Serial anti-PLA2R titers:** Declining titers predict remission; rising titers predict relapse [cite:Robbins 10e Ch 20]